Eloxx Pharmaceuticals, Inc. ELOX
Set alert
13.45 USD +0.27 +2.05%
At close · Oct 30
13.90 +0.45 +3.35%
After hours · Oct 30, 4:00 PM ET
12.99 Day range 13.77
10.95 52-week range 20.98
- YTD
- +22.16%
- 1 year
- +22.16%
- Open
- 13.35
- Prev close
- 13.18
- Mkt cap
- 54.29M
- Vol
- 13.99K
- Avg vol
- 34.36K
- EPS
- 3.52
- P/E
- 3.82
- Div yield
- 0.00%
More statistics
- Low
- 12.99
- High
- 13.77
- Forward P/E
- -0.87
- Beta
- 2.61
- Short ratio
- 0.63
- Inst. own
- 43.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 6.06
- 200-d avg
- 5.01
- 1y target
- 55.00
MAX chart
Signals (33)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 2 days ago |
| SMA: Bearish | Oct 28, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 5 days ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| RSI: Overbought | Aug 11, 2026 | 2 months ago |
| RSI: Overbought | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 28, 2026 | 3 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| SMA: Bullish | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bullish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
Key statistics
- Market cap
- 16.85M
- Enterprise value
- 30.29M
- Trailing P/E
- 0.00
- Forward P/E
- -0.87
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -18.10
- Beta
- 2.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.70M
- Total cash
- 4.90M
- Total debt
- 18.77M
- Return on equity
- 0.00%
- Shares outstanding
- 2.17M
- Short % of float
- 2.34%
- 50-day average
- 6.06
- 200-day average
- 5.01
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 55.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate -1.54.
Financials — quick view
ELOX Revenue — quarterly 0
ELOX Net income — quarterly -4.50M
ELOX EPS — quarterly -0.66
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | -1.43 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -1.97 | -1.31 | +0.66 | +33.50% |
| Aug 14, 2023 | Jun 1, 2023 | -1.54 | -1.96 | -0.42 | -27.27% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 11, 2023 | Oppenheimer | main | Outperform | Outperform |
| Apr 6, 2023 | Oppenheimer | reit | — | Outperform |
| May 23, 2022 | Piper Sandler | main | — | Overweight |
| May 9, 2022 | HC Wainwright & Co. | main | — | Neutral |
| Dec 17, 2021 | Oppenheimer | init | — | Outperform |
| Nov 18, 2021 | HC Wainwright & Co. | main | — | Neutral |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eloxxpharma.com
News
- Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
- Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40
- Eloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations
- Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.
- Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
- This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
- Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
Your note
Sign in to keep a note on ELOX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGGARWAL SUMIT | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 30, 2021 | 197,225 |
| BELLOFF NEIL S. | Chief Operating Officer | Conversion of Exercise of derivative security | Jul 29, 2021 | 32,699 |
| GEFFKEN DANIEL E | Chief Financial Officer | Purchase | Nov 28, 2021 | 50,000 |
| KARIV TOMER | Director | Purchase | May 12, 2021 | 0 |
| MODUR VIJAY M.D., PH.D. | Officer | Conversion of Exercise of derivative security | Nov 30, 2021 | 154,953 |
| NUSSBAUM RAN | Director | Purchase | May 12, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SilverArc Capital Management, LLC | 2.50% | 54,075 | 420.70K | Mar 30, 2023 |
| Menora Mivtachim Holdings Ltd. | 2.42% | 52,355 | 407.32K | Mar 30, 2023 |
| American Financial Group Inc. | 1.71% | 37,000 | 287.86K | Mar 30, 2023 |
| Harel Insurance Investments & Financial Services Ltd. | 1.36% | 29,410 | 228.81K | Mar 30, 2023 |
| Altshuler Shaham Ltd | 1.16% | 25,123 | 195.46K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 0.95% | 20,686 | 160.94K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.95% | 20,636 | 160.55K | Dec 30, 2022 |
| Vanguard Total Stock Market Index Fund | 0.78% | 16,840 | 131.01K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.41% | 8,984 | 69.89K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.14% | 2,954 | 22.98K | Feb 27, 2023 |
| Fidelity NASDAQ Composite Index ETF | 0.14% | 2,943 | 22.90K | Mar 30, 2023 |
| Fidelity Total Market Index Fund | 0.13% | 2,779 | 21.62K | Feb 27, 2023 |